New drug combo trial offers hope for Tough-to-Treat thyroid cancer
NCT ID NCT04061980
Summary
This study is testing whether two targeted cancer drugs (encorafenib and binimetinib), given with or without an immunotherapy drug (nivolumab), can help control advanced thyroid cancer that has a specific genetic change (BRAF V600 mutation) and has stopped responding to standard radioactive iodine treatment. The trial aims to see if these combinations are safe and can shrink tumors or slow their growth. It is for a small group of patients with this specific type of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
Conditions
Explore the condition pages connected to this study.